Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo comparator

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,804 result(s) found for: Placebo comparator. Displaying page 59 of 91.
    «« First « Previous 55  56  57  58  59  60  61  62  63  Next» Last»»
    EudraCT Number: 2007-005791-14 Sponsor Protocol Number: SIG110762 Start Date*: 2009-02-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asth...
    Medical condition: Mild asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014543-36 Sponsor Protocol Number: AC4113073 Start Date*: 2009-11-17
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001810-32 Sponsor Protocol Number: EP-101-03 Start Date*: 2011-08-23
    Sponsor Name:Elevation Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005551-27 Sponsor Protocol Number: CCD-06366AA1-01 Start Date*: 2017-12-11
    Sponsor Name:Chiesi Farmaceutici
    Full Title: A First in Human Randomised, Double-Blind, Placebo-Controlled Study of Single Ascending Doses in Healthy Male Volunteers and Repeated Ascending Dose in Asthmatic Patients Followed by a 3-Way Cross-...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) Patients with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006337-27 Sponsor Protocol Number: 03140-203 Start Date*: 2009-03-24
    Sponsor Name:EPIX Pharmaceuticals, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRX-03140 AS MONOTHERAPY IN SUBJECTS WITH ALZHEIMER’S DISEASE
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-007307-91 Sponsor Protocol Number: H8Y-MC-HBBR Start Date*: 2009-09-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017853-36 Sponsor Protocol Number: H8Y-MC-HBBO Start Date*: 2010-09-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004092-22 Sponsor Protocol Number: HH3110163 Start Date*: 2008-09-03
    Sponsor Name:GlaxSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy a...
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022280-35 Sponsor Protocol Number: SSD113434 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline
    Full Title: A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis.
    Medical condition: subjects with moderate or severe atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001163-12 Sponsor Protocol Number: 1604 Start Date*: 2016-06-26
    Sponsor Name:Herlev University Hospital, Oncology Dept.
    Full Title: A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) with or without T-ChOSTM as adjuvant therapy in patients with surgically rese...
    Medical condition: pt with surgically resected pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001670-28 Sponsor Protocol Number: BER-1272-0058-I Start Date*: 2013-03-18
    Sponsor Name:Medizinische Fakultät der Technischen Universität München
    Full Title: Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema BERINERT Randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema
    Medical condition: Angiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004870 10002425 Angioedemas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005115-29 Sponsor Protocol Number: RA1104046 Start Date*: 2005-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021984-33 Sponsor Protocol Number: WN25333 Start Date*: 2011-05-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exa...
    Medical condition: Acute Symptoms of Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    12.1 10001064 Acute schizophrenia LLT
    12.1 10039630 Schizophrenia exacerbated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012213-22 Sponsor Protocol Number: PHX1149-PROT306 Start Date*: 2009-11-11
    Sponsor Name:Phenomix Corporation
    Full Title: A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Rena...
    Medical condition: Type II Diabetes Mellitus in subjects with Moderate and Severe Renal Impairment including subjects on Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004481-16 Sponsor Protocol Number: VRA105345 Start Date*: 2005-12-19
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar too...
    Medical condition: Dental pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013269-24 Sponsor Protocol Number: 1268.41 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ...
    Medical condition: Allergic rhinitis due to pollen
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001726 Allergic rhinitis due to pollen LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010221-39 Sponsor Protocol Number: MB102035 Start Date*: 2009-12-18
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control ...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002590-44 Sponsor Protocol Number: 3175A1-202-WW Start Date*: 2007-01-25
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSE REGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILY FOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEE
    Medical condition: ACTIVE OSTEOARTHRITIS OF THE KNEE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002517-35 Sponsor Protocol Number: V00162PI2024A Start Date*: 2013-09-05
    Sponsor Name:Pierre Fabre Médicament/Institut de Recherche Pierre Fabre
    Full Title: Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: Removed from public view
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 55  56  57  58  59  60  61  62  63  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:24:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA